BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 29, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

May 6, 2020

View Archived Issues
Fitbit Ionic product image

Fitbit targets AF with large-scale, virtual study

Wearables giant Fitbit Inc. has kicked off its first large-scale, virtual study to evaluate how well its wrist-worn technology can spot episodes of irregular heart rhythm that might indicate atrial fibrillation (AF). The study, part of a broader plan to equip Fitbit devices with new tools to speed the detection of a range of conditions, is open to people in the U.S. ages 22 and older who own a Fitbit that tracks heart rate. Read More
coronavirus-antibodies-immunity.png

FDA’s Stenzel highlights sensitivity, specificity for COVID-19 antibody testing

The U.S. FDA continues to modify its emergency use authorization (EUA) policy for testing for the SARS-CoV-2 virus, although workplace testing is still on the agency’s to-do list. The FDA’s Tim Stenzel noted on a May 6 briefing that serological tests for antibodies must now demonstrate an overall sensitivity of 90% and overall specificity of 95%, a set of standards that might challenge some tests that are available under the EUA policy. Read More
Athersys researchers with bioreactor in the lab

Pass the MUST-ARDS: Athersys starts pivotal study for stem cells to treat COVID-19-induced ARDS

Stem cells haven’t exactly panned out as hoped when it comes to approved therapeutics. There are only a couple that have received a nod from the FDA in very specific indications. But the ongoing COVID-19 pandemic could push stem cells back into the limelight and more firmly establish them as therapeutically relevant. Read More
Kidneys

Caredx teams up with Weill Cornell Medicine on Uromap

Brisbane, Calif.-based Caredx Inc. has reported a strategic alliance with Weill Cornell Medicine that makes the company the exclusive development and commercialization partner for Uromap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients. Read More
Cytosorb product image

Cytosorbents introduces Cytosorb in Mexico

After a long approval process, Monmouth Junction N.J.-based Cytosorbents Corp. received clearance to bring its Cytosorb blood purification technology to treat cytokine storm and deadly inflammation in critically ill and cardiac surgery patients, to the Mexican market. The COVID-19 pandemic may delay marketing plans to roll-out the product in the Latin American country. Read More

The next pandemic

Even as the world grapples with COVID-19, researchers and public health officials are trying to apply its lessons to future outbreaks. In our series “The next pandemic,” BioWorld explores the strategies and technologies that could improve the fight against future outbreaks, from robust surveillance to rapid vaccines. Read More

Appointments and advancements for May 6, 2020

New hires and promotions in the med-tech industry, including: Brainsway, Eltitechgroup, Mimedx Group, Orthopediatrics, Ossdsign. Read More

Financings for May 6, 2020

Med-tech firms raising money in public or private financings, including: Applied DNA, Limbix, Silk Road Medical, Titan Medical. Read More

In the clinic for May 6, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Baxter. Read More

Other news to note for May 6, 2020

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alivecor, Biointellisense, Brightinsight, CSL Behring, Dariohealth, Fiagon, Foracare, Inogen, Kubtec, Labcorp, Meridian Bioscience, Quantumdx, Microbix, Nimble Therapeutics, Roche, Orthopediatrics, Perkinelmer, Pharmacyte, Rensselaer, Smith+Nephew, Thermo Fisher Scientific, Twist Bioscience. Read More

Regulatory actions for May 6, 2020

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Headsafe, Foundation Medicine, Setpoint Medical. Read More

Regulatory front for May 6, 2020

The latest global regulatory news, changes and updates affecting medical devices and technologies. Read More

BioWorld MedTech’s Orthopedics Extra for May 6, 2020

Keeping you up to date on recent developments in orthopedics, including: Scientists regenerate neurons in mice with spinal cord injury and optic nerve damage; Trial questions benefits of organic nitrates for bone health; Mind-controlled arm prostheses that 'feel' are now a part of everyday life; Biomaterial immune control discoveries could reduce implant rejection. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 28, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 28, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing